Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals U.S., Inc. (Actelion) is a biopharmaceutical company. The company principally engaged in research, development, selling and marketing of biopharmaceutical products. The company provides three types biopharmaceutical products namely, tracleer, zavesca, and ventavis. The company announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York heart association class III and IV pulmonary arterial hypertension (PAH). Tracleer was approved in 2001 as the first oral treatment for PAH. Actelion is working as a subsidiary of Actelion, Ltd. The company is headquartered in South San Francisco in California, the US.